SRT联合拉帕替尼治疗HER2阳性乳腺癌脑转移疗效及预后分析

doi:10.11904/j.issn.1002-3070.2021.06.007

实用肿瘤学杂志 ›› 2021, Vol. 35 ›› Issue (6): 523-528.doi: 10.11904/j.issn.1002-3070.2021.06.007

SRT联合拉帕替尼治疗HER2阳性乳腺癌脑转移疗效及预后分析

罗波¹, 张曲¹, 郑红梅², 梁新军³, 周小妹¹, 吴新红²

1.湖北省肿瘤医院放疗中心(武汉 430079);
2.湖北省肿瘤医院乳腺外科;
3.湖北省肿瘤医院腹部肿瘤内科

收稿日期:2020-10-12 修回日期:2021-03-30 出版日期:2021-12-28 发布日期:2021-12-17
通讯作者: 吴新红,E-mail:wuxhg2020@163.com
作者简介:罗波,男,(1980-),博士,副主任医师,从事乳腺肿瘤临床和基础的研究。
基金资助:
湖北省自然科学基金项目(编号:2018CFC848,2017CFB555);湖北省卫生计生委项目(编号:WJ2017M142);国家自然科学基金项目(编号:81201795)

Efficacy and prognosis of SRT combined with lapatinib in the treatment of HER2-positive breast cancer brain metastasis

LUO Bo¹, ZHANG Qu¹, ZHENG Hongmei², LIANG Xinjun³, ZHOU Xiaomei¹, WU Xinhong²

1. Department of Radiotherapy Center,Hubei Cancer Hospital,Wuhan 430079,China;
2. Department of Breast Cancer Surgery,Hubei Cancer Hospital;
3. Department of Abdominal Tumor,Hubei Cancer Hospital

Received:2020-10-12 Revised:2021-03-30 Online:2021-12-28 Published:2021-12-17

摘要/Abstract

摘要： 目的探讨立体定向放射治疗(Stereotactic radiotherapy,SRT)联合拉帕替尼治疗HER2阳性乳腺癌脑转移的疗效及预后。方法回顾性分析91例HER2阳性乳腺癌脑转移患者接受拉帕替尼靶向治疗的同时接受全脑放疗或SRT的情况,其中42例患者接受SRT的同时进行拉帕替尼联合卡培他滨治疗(SRT组),另外49例患者采用全脑放疗同时进行拉帕替尼联合卡培他滨治疗(全脑放疗组)。评价其疗效和毒性,定期随访,并行多因素Cox回归分析其预后相关因素。结果放疗结束后1月SRT组脑部病灶客观缓解率为92.86%(39/42),全脑放疗组客观缓解率为77.55%(38/49),SRT组优于全脑放疗组(χ²=4.070,P=0.044)。SRT组和全脑组12个月受照射肿瘤病灶无进展生存率分别为95.20%及83.10%, SRT组优于全脑放疗组(χ²=10.851,P=0.001)。 SRT组无颅内转移生存率与全脑放疗组无统计学差异(P＞0.05)。SRT组和全脑放疗组1年生存率分别为85.70%和69.40%,2年生存率分别为66.70%和55.10%,两组中位生存期分别为31.56个月和25.00个月,SRT组优于全脑放疗组(P=0.002)。多因素Cox回归分析结果表明无颅外转移(HR=0.527,95% CI:0.290~0.957,P=0.035),颅内病灶≤3个(HR=2.457,95% CI:1.223~4.933,P=0.012),放疗方式SRT(HR=1.746,95% CI:1.055~2.888,P=0.030)是HER2阳性乳腺癌脑转移放疗预后的独立保护因素。结论 SRT联合拉帕替尼在局部控制率以及生存率上优于全脑放疗联合拉帕替尼。颅内病灶个数少、无颅外转移灶和放疗方式是HER2阳性乳腺癌脑转移治疗的良好预后因素。

关键词: 乳腺癌, 脑转移, 立体定向放疗, 拉帕替尼

Abstract: Objective The aim of this study was to investigate the efficacy and prognosis of stereotactic radiotherapy(stereotactic radiotherapy,SRT)combined with lapatinib in the treatment of HER2-positive breast cancer brain metastasis. Methods A total of 91 patients with HER2-positive breast cancer brain metastases receiving lapatinib targeted therapy and whole brain radiotherapy or SRT were retrospectively analyzed.Forty-two patients received SRT and lapatinib combined with capecitabine treatment(SRT group)and another 49 patients were treated with whole brain radiotherapy and lapatinib combined with capecitabine.Curative effect and toxicity were further evaluated.Regular follow-up The related prognostic factors of patients were analyzed by multivariate Cox ragression. Results The objective response rate of brain lesions in the SRT group was 92.86%(39/42)after the end of radiotherapy;the objective response rate of the whole brain radiotherapy group was 77.55%(38/49),and the SRT group was better than the whole brain radiotherapy group(χ²=4.070,P=0.044).The Irradiated lesions progression free survival rates of 12 months in the SRT group and whole brain group were 95.20% and 83.10%,respectively.The SRT group was better than the whole brain radiotherapy group(χ²=10.851,P=0.001).There was no significant difference in the intracranial metastasis rate between the SRT group and whole brain radiotherapy group.The 1-year survival rates of the SRT group and whole brain radiotherapy group were 85.70%,69.40%,and the 2-year survival rates were 66.70% and 55.10%,respectively.The median survival time of the two groups was 31 months and 25 months,respectively.The SRT group was better than that in the whole brain radiotherapy group(P=0.002).Cox multivariate analysis showed no extracranial metastasis(HR=0.527,95% CI:0.290~0.957,P=0.035),intracranial lesions ≤3(HR= 2.457,95% CI:1.223~4.933,P=0.012),The radiotherapy SRT(HR=1.746,95% CI:1.055-2.888,P=0.030)was an independent protective factors for the prognosis of radiotherapy for brain metastases from HER2-positive breast cancer. Conclusion SRT combined with lapatinib is superior to whole brain radiotherapy combined with lapatinib in terms of local control rate and survival.Few intracranial lesions and no extracranial metastases and radiotherapy SRT is a good prognostic factor for the treatment of brain metastases from HER2-positive breast cancer.

Key words: Breast cancer, Brain metastasis, Stereotactic radiotherapy, Lapatinib

中图分类号:

R730.55

罗波, 张曲, 郑红梅, 梁新军, 周小妹, 吴新红. SRT联合拉帕替尼治疗HER2阳性乳腺癌脑转移疗效及预后分析[J]. 实用肿瘤学杂志, 2021, 35(6): 523-528.

LUO Bo, ZHANG Qu, ZHENG Hongmei, LIANG Xinjun, ZHOU Xiaomei, WU Xinhong. Efficacy and prognosis of SRT combined with lapatinib in the treatment of HER2-positive breast cancer brain metastasis[J]. Journal of Practical Oncology, 2021, 35(6): 523-528.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2021.06.007

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2021/V35/I6/523

参考文献

1 Olson EM,Najita JS,Sohl J,et al.Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post trastuzumab era[J].Breast,2013,22(4):525-531.
2 Sperduto PW,Kased N,Roberge D,et al.Summary report on the graded prognostic assessment:an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases[J].J Clin Oncol,2012,30(4):419-425.
3 Venkatesan P.SRT is non-inferior to WBRT for brain metastases[J].Lancet Oncol,2018,19(8):e386.
4 Bachelot T,Romieu G,Campone M,et al.Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer(LANDSCAPE):a single-group phase 2 study[J].Lancet Oncol,2013,14(1):64-71.
5 Braccini AL,Azria D,Thezenas S,et al.Prognostic factors of brain metastases from breast cancer:impact of targeted therapies[J].Breast,2013,22(5):993-998.
6 Miller JA,Kotecha R,Ahluwalia MS,et al.Overall survival and the response to radiotherapy among molecular subtypes of breast cancer brain metastases treated with targeted terapies[J].Cancer,2017,123(12):2283-2293.
7 Brown PD,Ballman KV,Cerhan JH,et al.Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease(NCCTG N107C/CEC·3):a multicentre,randomised,controlled,phase 3 trial[J].Lancet Oncol,2017,18(8):1049-1060.
8 Bernhardt D,Hommertgen A,Schmitt D,et al.Whole brain radiation therapy alone versus radiosurgery for patients with 1-10 brain metastases from small cell lung cancer(ENCEPHALON Trial):study protocol for a randomized controlled trial[J].Trials,2018,19(1):388.
9 De Ieso PB,Schick U,Rosenfelder N,et al.Breast cancer brain metastases-a 12-year review of treatment outcomes[J].Breast,2015,24(4):426-433.
10 Gaia G,Maria VD,Tommaso G,et al.Beyond breast specific-graded prognostic assessment in patients with brain metastases from breast cancer:treatment impact on outcome[J].J Neurooncol,2017,131(2):369-376.

[1]	史润泽, 李志高. 三阴性乳腺癌各亚型精准医疗策略研究进展[J]. 实用肿瘤学杂志, 2021, 35(6): 529-533.
[2]	李响, 胡洋, 张清媛. 肿瘤突变负荷作为乳腺癌免疫治疗的新兴生物标志物的研究进展[J]. 实用肿瘤学杂志, 2021, 35(6): 568-571.
[3]	周天虹, 顾秀瑛, 姚芳, 宋述铭. 乌鲁木齐市2014—2018年度乳腺癌筛查结果分析[J]. 实用肿瘤学杂志, 2021, 35(5): 391-395.
[4]	马补换, 刘彩霞. Jagged1促进乳腺癌发生发展及远处转移的研究进展[J]. 实用肿瘤学杂志, 2021, 35(5): 452-457.
[5]	秦朝, 李江, 郑亚迪, 王飞, 曹巍, 许永杰, 余一雯, 赵亮, 于欣阳, 陈宏达, 任建松, 王勇, 李静, 李霓, 陈万青. 中国城市乳腺癌高危人群筛查依从性及其相关因素分析[J]. 实用肿瘤学杂志, 2021, 35(4): 291-296.
[6]	郭兰伟, 张韶凯, 刘曙正, 郑黎阳, 陈琼, 曹小琴, 孙喜斌, 张建功. 河南省城市地区乳腺癌筛查依从性及其影响因素分析[J]. 实用肿瘤学杂志, 2021, 35(4): 307-313.
[7]	李钰莹, 张悦. Sirtuins在乳腺癌中作用机制的研究进展[J]. 实用肿瘤学杂志, 2021, 35(3): 277-281.
[8]	提谦, 张清媛. CDK4/6抑制剂联合内分泌治疗晚期乳腺癌[J]. 实用肿瘤学杂志, 2021, 35(3): 287-290.
[9]	杨敏, 张娇燕, 段丹, 徐兵河. 乳腺癌照顾者研究的文献计量学及可视化分析[J]. 实用肿瘤学杂志, 2021, 35(2): 110-116.
[10]	王健宇, 张显玉, 庞达. Luminal A型乳腺癌新辅助化疗疗效的影响因素分析[J]. 实用肿瘤学杂志, 2021, 35(2): 131-136.
[11]	胡洋, 张清媛. PARP抑制剂治疗BRCA1/2突变转移性乳腺癌的研究进展[J]. 实用肿瘤学杂志, 2021, 35(2): 184-187.
[12]	朱云芳,文洪梅,秦明芳,石青萍,成会荣,高娇,陈杨. 2011—2016年云南省肿瘤登记地区女性乳腺癌发病和死亡情况分析[J]. 实用肿瘤学杂志, 2021, 35(1): 18-22.
[13]	鲍瑜,朱立建(综述),钱江(审校). 抗血管生成药物治疗肺癌脑转移的研究新进展[J]. 实用肿瘤学杂志, 2021, 35(1): 91-96.
[14]	牛明, 于歌. 促进乳腺癌增殖转移和肿瘤干细胞特征的研究[J]. 实用肿瘤学杂志, 2020, 34(6): 518-523.
[15]	刘红, 鲁海玲, 蔡莉. 影像学预测乳腺癌患者预后及新辅助化疗反应的研究进展[J]. 实用肿瘤学杂志, 2020, 34(6): 535-539.

SRT联合拉帕替尼治疗HER2阳性乳腺癌脑转移疗效及预后分析

Efficacy and prognosis of SRT combined with lapatinib in the treatment of HER2-positive breast cancer brain metastasis

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价